赖氨酸降低疗法与吡哆醇依赖性癫痫患者认知结局的关联
研究纳入国际吡哆醇依赖性癫痫登记处60例患者,分析吡哆醇联合赖氨酸降低疗法(LRTs)与发育测试评分的关联。任何年龄联合LRTs较单用吡哆醇评分提高6.9分(95%CI -2.7至16.5),未达显著;生后6个月内联合LRTs评分提高21.9分(95%CI 1.7至42.0),达显著。
要点
- 吡哆醇联合LRTs较单用吡哆醇发育评分提高6.9分(95%CI -2.7至16.5),无显著差异。
- 生后6个月内联合LRTs评分提高21.9分(95%CI 1.7至42.0),有显著差异。
- 早期婴儿期联合吡哆醇与LRTs可能改善发育结局。
核心结论
- 任何年龄吡哆醇联合LRTs与发育测试轻度改善相关,早期婴儿期治疗与临床显著的发育测试评分提高相关。
研究设计与样本
- 研究为来自国际吡哆醇依赖性癫痫患者登记处的参与者,招募时间为2014年8月至2021年3月。
- 共纳入60例参与者,获得112个发育测试评分。
主要发现
- 吡哆醇联合LRTs较单用吡哆醇发育测试评分平均提高6.9分(95%CI -2.7至16.5),未达统计学显著。
- 生后6个月内联合LRTs亚组共8例参与者,获得14个发育测试评分,评分平均提高21.9分(95%CI 1.7至42.0),达统计学显著。
临床怎么用
- 作者认为早期婴儿期联合吡哆醇与LRTs治疗很重要。
- 作者指出研究结果有助于理解PDE-ALDH7A1智力与发育障碍的机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is a developmental epileptic encephalopathy characterized by seizure improvement after pyridoxine supplementation. Adjunct lysine reduction therapies (LRTs) reduce the accumulation of putative neurotoxic metabolites with the goal to improve developmental outcomes. Our objective was to examine the association between treatment with LRTs and cognitive outcomes. METHODS: Participants were recruited from within the International Registry for Patients with Pyridoxine-Dependent Epilepsy from August 2014 through March 2021. The primary outcome was standardized developmental test scores associated with overall cognitive ability. The relationship between test scores and treatment was analyzed with multivariable linear regression using a mixed-effects model. A priori, we hypothesized that treatment in early infancy with pyridoxine and LRTs would result in a normal developmental outcome. A subanalysis was performed to evaluate the association between cognitive outcome and LRTs initiated in the first 6 months of life. RESULTS: A total of 112 test scores from 60 participants were available. On average, treatment with pyridoxine and LRTs was associated with a nonsignificant increase of 6.9 points (95% CI -2.7 to 16.5) on developmental testing compared with treatment with pyridoxine alone. For the subanalysis, a total of 14 developmental testing scores were available from 8 participants. On average, treatment with pyridoxine and LRTs in the first 6 months of life was associated with a significant increase of 21.9 points (95% CI 1.7-42.0) on developmental testing. DISCUSSION: Pyridoxine and LRTs at any age was associated with mild improvement in developmental testing, and treatment in early infancy was associated with a clinically significant increase in developmental test scores. These results provide insight into the mechanism of intellectual and developmental disability in PDE-ALDH7A1 and emphasize the importance of treatment in early infancy with both pyridoxine and LRTs. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in PDE-ALDH7A1, pyridoxine and LRTs compared with pyridoxine alone is not significantly associated with overall higher developmental testing scores, but treatment in the first 6 months of life is associated with significantly higher developmental testing scores.
引用
- Coughlin CR, Tseng LA, Bok LA, et al. Association Between Lysine Reduction Therapies and Cognitive Outcomes in Patients With Pyridoxine-Dependent Epilepsy. Neurology. 2022. PMID: 36008148. doi:10.1212/WNL.0000000000201222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。